Evaluation of new putative tumor markers for melanoma
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: The early diagnosis of recurrent melanoma can contribute to better outcome if the disease can be surgically resected or if the metastases are responsive to systemic therapies. Lipid-associated sialic acid (LASA-P) and the S-100 protein (S-100) were evaluated as tumor markers for melanoma with the goal of early detection of recurrence.
Methods: Sixty-seven patients were identified who had levels of S-100 and LASA-P drawn during their clinical course. A multivariate regression analysis was performed to determine the significance of the serum markers in relation to other prognostic factors for melanoma.
Results: After a median follow-up of 30 months, 58 patients had recurrences, and 49 patients died of disease. LASA-P elevation was not associated with the time to recurrence (p=0.2176) or survival (p=0.2507). S-100 positivity was a significant predictor of recurrence (p<0.0001) and survival (p=0.0059). The median time to recurrence for S-100-positive and S-100-negative patients was 7.6 and 33.8 months, respectively. The median survival time was 59.2 months for S-100-negative patients and 29.6 months for patients positive for S-100.
Conclusions: Serum S-100 shows significant correlations to both time to recurrence and survival and could be useful in the clinical detection of malignant melanoma.
- Evaluation of new putative tumor markers for melanoma
Annals of Surgical Oncology
Volume 3, Issue 6 , pp 558-563
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Metastatic melanoma
- Tumor marker
- Industry Sectors
- Author Affiliations
- 1. Cutaneous Oncology Program, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA
- 2. Division of Medical Oncology, Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, Florida, USA
- 3. Dianon Systems, Inc., Stratford, Connecticut, USA